Literature DB >> 18465362

Type 2 diabetes mellitus as risk factor for colorectal cancer.

Jutta M Berster1, Burkhard Göke.   

Abstract

Colorectal cancer occurs more frequently in patients with type 2 diabetes mellitus. The hyperinsulinemia-hypothesis suggests that elevated levels of insulin and free IGF-1 promote proliferation of colon cells and lead to a survival benefit of transformed cells, ultimately resulting in colorectal cancer. In patients with type 2 diabetes mellitus, epidemiological studies show an increased risk for colorectal cancer and an even higher risk if patients are treated with sulphonylureas or insulin. Moreover, tumour progression at hyperinsulinemia is more rapid and tumour-associated mortality is increased. Colorectal cancer can be avoided by screening. Recommendations for colorectal cancer screening should employ the recent epidemiologic evidence. All patients with type 2 diabetes mellitus should be recommended to undergo colonoscopy before starting insulin therapy, and screening intervals should not exceed 5 years. For this concept, a review of the evidence is presented, and a screening algorithm for colorectal cancer in patients with type 2 diabetes mellitus is proposed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18465362     DOI: 10.1080/13813450802008455

Source DB:  PubMed          Journal:  Arch Physiol Biochem        ISSN: 1381-3455            Impact factor:   4.076


  47 in total

Review 1.  Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms.

Authors:  Olga Giouleme; Michael D Diamantidis; Marios G Katsaros
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population.

Authors:  Roger C Zhu; Kirk Rattanakorn; Steven Pham; Divya Mallam; Thomas McIntyre; Moro O Salifu; Irini Youssef; Samy I McFarlane; Shivakumar Vignesh
Journal:  Colorectal Cancer       Date:  2017-06-21

3.  Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative.

Authors:  Michael S Simon; Cynthia A Thomson; Erin Pettijohn; Ikuko Kato; Rebecca J Rodabough; Dorothy Lane; F Allan Hubbell; Mary Jo O'Sullivan; Lucille Adams-Campbell; Charles P Mouton; Judith Abrams; Rowan T Chlebowski
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-05-20       Impact factor: 4.254

4.  Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women.

Authors:  Juhua Luo; Rowan Chlebowski; Simin Liu; Katherine A McGlynn; Niyati Parekh; Donna L White; Karen L Margolis
Journal:  Cancer Causes Control       Date:  2012-05-24       Impact factor: 2.506

5.  Barriers and facilitators to colorectal cancer screening in Vietnamese Americans: a qualitative analysis.

Authors:  Amanda Kimura; Mo-Kyung Sin; Clarence Spigner; Anh Tran; Shin-Ping Tu
Journal:  J Cancer Educ       Date:  2014-12       Impact factor: 2.037

6.  Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in ApcMin/+ mice fed a high-fat diet.

Authors:  Kaori Fujiwara; Takuya Inoue; Yujiro Henmi; Yoshimasa Hirata; Yutaka Naka; Azusa Hara; Kazuki Kakimoto; Sadaharu Nouda; Toshihiko Okada; Ken Kawakami; Toshihisa Takeuchi; Kazuhide Higuchi
Journal:  Oncol Lett       Date:  2017-08-01       Impact factor: 2.967

7.  Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice.

Authors:  Jutta M Nagel; Jürgen Staffa; Ingrid Renner-Müller; David Horst; Michael Vogeser; Markus Langkamp; Andreas Hoeflich; Burkhard Göke; Frank T Kolligs; Christos S Mantzoros
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

8.  Design of an insulin analog with enhanced receptor binding selectivity: rationale, structure, and therapeutic implications.

Authors:  Ming Zhao; Zhu-li Wan; Linda Whittaker; Bin Xu; Nelson B Phillips; Panayotis G Katsoyannis; Faramarz Ismail-Beigi; Jonathan Whittaker; Michael A Weiss
Journal:  J Biol Chem       Date:  2009-09-22       Impact factor: 5.157

Review 9.  Metabolic syndrome and cancer.

Authors:  Pooja Pothiwala; Sushil K Jain; Subhashini Yaturu
Journal:  Metab Syndr Relat Disord       Date:  2009-08       Impact factor: 1.894

10.  Obesity and colorectal cancer.

Authors:  Irena Gribovskaja-Rupp; Lauren Kosinski; Kirk A Ludwig
Journal:  Clin Colon Rectal Surg       Date:  2011-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.